Ryvu Therapeutics Sa
Clinical trials sponsored by Ryvu Therapeutics Sa, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial Results expected Dec 2026 (estimated)
- Cancer drug RVU120 gets extended trial for ongoing patients Results expected Dec 2026 (estimated)
- Two-Drug combo targets leukemia that outsmarted its first treatment Results expected Aug 2027 (estimated)
-
Oral drug RVU120 put to the test against advanced solid tumors
Disease control Stopped earlyResearchers are testing an experimental oral drug called RVU120 in adults with advanced or metastatic solid tumors that have worsened after standard treatments. The trial has two parts: first, they check safety and find the best dose; second, they measure how well the drug shrink…
Phase 1/2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
Disease control Stopped earlyResearchers are testing RVU120, an experimental oral drug, in adults with acute myeloid leukemia (AML) that has come back or stopped responding to treatment, or with high-risk myelodysplastic syndrome (MDS). The drug blocks two enzymes called CDK8 and CDK19, which may play a role…
Phase 1 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a CDK8/CDK19 blocker help when leukemia and MDS return?
Disease control Stopped earlyResearchers are testing an experimental drug called RVU120 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or stopped responding to treatment. RVU120 blocks two proteins, CDK8 and CDK19, that may help cancer cells grow. T…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Stopped earlyThis Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC